Who are FSME-Immune vaccination's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): fIPV (0.2mL) IM, Havrix+Healive, Hepatitis A (control), Havrix (HAV), Havrix Junior, Havrix 720 Junior.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fsme-immune-vaccination.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

FSME-Immune vaccination — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

FSME-Immune vaccination (FSME-Immune vaccination) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inactivated viral vaccine. Area: Immunology / Infectious Disease.

marketed Inactivated viral vaccine Tick-borne encephalitis virus (TBEV) envelope proteins Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

FSME-Immune vaccination (FSME-Immune vaccination) — Medical University of Vienna. FSME-Immune is an inactivated tick-borne encephalitis virus vaccine that stimulates the immune system to produce antibodies and cellular immunity against TBEV.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
FSME-Immune vaccination TARGET	FSME-Immune vaccination	Medical University of Vienna	marketed	Inactivated viral vaccine	Tick-borne encephalitis virus (TBEV) envelope proteins
fIPV (0.2mL) IM	fIPV (0.2mL) IM	Centers for Disease Control and Prevention	marketed	Inactivated viral vaccine
Havrix+Healive	Havrix+Healive	Sinovac Biotech Co., Ltd	marketed	Combination inactivated viral vaccine	Hepatitis A virus antigen; Hepatitis B surface antigen (HBsAg)
Hepatitis A (control)	Hepatitis A (control)	International Vaccine Institute	marketed	inactivated viral vaccine	Hepatitis A virus surface antigens
Havrix (HAV)	Havrix (HAV)	Pfizer	marketed	Inactivated viral vaccine	Hepatitis A virus antigen
Havrix Junior	Havrix Junior	GlaxoSmithKline	marketed	Inactivated viral vaccine	Hepatitis A virus antigen
Havrix 720 Junior	Havrix 720 Junior	Chiang Mai University	marketed	Inactivated viral vaccine	Hepatitis A virus surface antigen

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inactivated viral vaccine class)

Sinovac Biotech Co., Ltd · 9 drugs in this class
Sanofi Pasteur, a Sanofi Company · 9 drugs in this class
GlaxoSmithKline · 5 drugs in this class
Valneva Austria GmbH · 4 drugs in this class
Medical University of Vienna · 3 drugs in this class
Centers for Disease Control and Prevention · 3 drugs in this class
China National Biotec Group Company Limited · 2 drugs in this class
Statens Serum Institut · 2 drugs in this class
Institute of Medical Biology, Chinese Academy of Medical Sciences · 2 drugs in this class
Crucell Holland BV · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). FSME-Immune vaccination — Competitive Intelligence Brief. https://druglandscape.com/ci/fsme-immune-vaccination. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab